Medical and preventive institutions of the Lipetsk region received 550 packages of an innovative drug for the treatment of patients with COVID-19

On April 14, 2021, 3 medical and preventive institutions (GUZ "Lipetsk Regional Clinical Infectious Diseases Hospital", GUZ "Lipetsk City Hospital No. 4 "Lipetsk-Med", GUZ " Yelets City Hospital No. 1 named after N. A. Semashko") The Lipetsk region has received a centralized delivery of 550 packages of a drug for the treatment of moderate forms of the new coronavirus infection COVID-19-a domestic biotechnological drug Artlegia-as part of a charity campaign conducted by its manufacturer, the R-Pharm group of companies.

In the Lipetsk region, a number of measures are being implemented to counter the spread of the SARS-CoV-2 coronavirus. For more than a year, since the beginning of the pandemic, the region has regularly carried out various activities aimed at improving the sanitary and epidemiological situation. A set of preventive measures, patient routing and specific prevention allow for moderate treatment of the consequences of the pandemic.

The drug received from R-Pharm, which is part of the Temporary Guidelines of the Ministry of Health of the Russian Federation for the Prevention, Diagnosis and Treatment of new coronavirus infection (COVID-19), will be an important tool for the implementation of this program and will be used as soon as possible to provide medical care to residents of the region.

R-Pharm Group of Companies is implementing a comprehensive strategy aimed at combating the new coronavirus infection COVID-19. As part of this project, the group of companies has already sent tens of thousands of packages of Artlegia to the regions of the country, the total cost of which exceeds 1 billion rubles.